Leukemia

Share:

The leukemia team at the Gill Center gives patients and their families what they need, when they need it: prompt diagnoses and exceptional care, access to the most advanced treatment protocols and nationally recognized leaders in pediatric leukemia research. 

Comprehensive Care

Comprehensive Care

Between 60 and 80 new patients enter the program each year. We treat every type of leukemia seen in children and adolescents, ranging from common to exceptionally rare.

Specific subtypes include:

  • T- and B-precursor acute lymphoblastic leukemias
  • Infant leukemia
  • Transient myeloproliferative disease
  • Acute and chronic myeloid leukemia 
  • Burkitt’s leukemia
  • Rare histologies, including acute blastic plasmacytoid neoplasms 

Patients enrolled in our program beneft from a multidisciplinary approach, including weekly leukemia team meetings where specialists and subspecialists review new patients, patients with treatment-related issues, patients following relapse and patients receiving standard therapies. Both patients and families benefit from the involvement of the Gill Center’s nurses, nurse practitioners, physician assistants, social workers, child life specialists, play therapists, psychologists, nutritionists, massage and aroma therapists, teachers, music therapists, chaplains, professional clowns and pain specialists. 

Program Highlights

Program Highlights

  • Between 60 and 80 new patients enrolled annually
  • Multidisciplinary approach, including care  for the entire family 
  • Exceptional monitoring and tracking of therapy doses 
  • Active enrollment of all patients in the Children’s Health Oncology Group and Therapeutic Advances in Childhood Leukemia (TACL) trials 
  • See also Stem Cell Transplant Program  
Advanced Treatment

Advanced Treatment 

Our leaders work in concert with other national pediatric oncology researchers to further develop leukemia therapies. Program Director, Naomi Winick, M.D., has served on the Children’s Health Oncology Group (COG) Acute Lymphoblastic Leukemia Committee since 2000, and is currently Chair of the Outcomes Committee for ALL. Tamra Slone, M.D., currently serves on the acute lymphoblastic leukemia trial for patients with high-risk disease and is co-chair of a study designed to understand the bone disease that can complicate leukemia therapy. Other staff physicians routinely serve on COG committees that design and administer clinical trials. 

The integration of our medical staff into the national research community ensures that we can offer patients the latest treatments and clinical trials. In 2013, Gill Center patients were enrolled in more than a dozen clinical trials, a result of our intentional effort to find an ideal trial for every patient.  

Research

Research

Beyond COG clinical trials, we conduct our own research. Current projects include: 

  • Early diagnosis of invasive fungal disease  and fungal prophylaxis in children with acute lymphoblastic and myelogenous leukemia
  • Identifying factors that predict risk for serious infection in children with leukemia 
  • Early phase clinical trials employing  new therapeutic agents to eradicate leukemia cells 
  • Laboratory research efforts at  UT Southwestern to understand  the biology of stem cells from  which leukemia begins  

Newsletter

Sign up to get updates on what's new at Children’s Health!

Contact Cancer and Blood Disorders

Phone: 214-456-2978

Appointment Request Form